PURPOSE: The aim of this study was to ascertain whether combined presynaptic and postsynaptic dopaminergic single-photon emission computed tomography (SPECT) scanning is useful for differentiation between patients with idiopathic Parkinson's disease (IPD), patients with multiple system atrophy of the striatonigral type (MSA) and healthy subjects. METHODS: SPECT measurements of the dopamine transporter (DAT) were done with 123I-beta-CIT, while for determination of the dopamine D2-like receptors (D2), 123I-epidepride was used. Clinical evaluation and SPECT scans were carried out in 14 patients with IPD, eight patients with MSA and 11 healthy age-matched control subjects. RESULTS: Putaminal DAT binding was reduced to 32% of control values in IPD and to 19% of control values in MSA . Significantly higher striatal asymmetry in DAT binding was found in MSA than in controls, but IPD patients had significantly higher asymmetry than MSA patients. Striatal D2 binding did not differ significantly between patients and healthy controls but the ratio between caudate DAT and D2 binding was significantly higher in patients with IPD than in those with MSA, even when disease severity was taken into account. CONCLUSION: Patients with reduced striatal 123I-beta-CIT binding and a side-to-side difference greater than 15% are likely to suffer from IPD. Patients with reduced striatal 123I-beta-CIT binding and a side-to-side difference of between 5% and 15% are more likely to have MSA. 123I-epidepride SPECT measurements may add further diagnostic information, since the ratio between DAT and D2 receptor binding is significantly higher in IPD than in MSA.
PURPOSE: The aim of this study was to ascertain whether combined presynaptic and postsynaptic dopaminergic single-photon emission computed tomography (SPECT) scanning is useful for differentiation between patients with idiopathic Parkinson's disease (IPD), patients with multiple system atrophy of the striatonigral type (MSA) and healthy subjects. METHODS: SPECT measurements of the dopamine transporter (DAT) were done with 123I-beta-CIT, while for determination of the dopamineD2-like receptors (D2), 123I-epidepride was used. Clinical evaluation and SPECT scans were carried out in 14 patients with IPD, eight patients with MSA and 11 healthy age-matched control subjects. RESULTS: Putaminal DAT binding was reduced to 32% of control values in IPD and to 19% of control values in MSA . Significantly higher striatal asymmetry in DAT binding was found in MSA than in controls, but IPD patients had significantly higher asymmetry than MSA patients. Striatal D2 binding did not differ significantly between patients and healthy controls but the ratio between caudate DAT and D2 binding was significantly higher in patients with IPD than in those with MSA, even when disease severity was taken into account. CONCLUSION:Patients with reduced striatal 123I-beta-CIT binding and a side-to-side difference greater than 15% are likely to suffer from IPD. Patients with reduced striatal 123I-beta-CIT binding and a side-to-side difference of between 5% and 15% are more likely to have MSA. 123I-epidepride SPECT measurements may add further diagnostic information, since the ratio between DAT and D2 receptor binding is significantly higher in IPD than in MSA.
Authors: L H Pinborg; C Videbaek; G M Knudsen; C G Swahn; C Halldin; L Friberg; O B Paulson; N A Lassen Journal: Synapse Date: 2000-06-15 Impact factor: 2.562
Authors: T L Jernigan; S L Archibald; C Fennema-Notestine; A C Gamst; J C Stout; J Bonner; J R Hesselink Journal: Neurobiol Aging Date: 2001 Jul-Aug Impact factor: 4.673
Authors: D J Brooks; V Ibanez; G V Sawle; E D Playford; N Quinn; C J Mathias; A J Lees; C D Marsden; R Bannister; R S Frackowiak Journal: Ann Neurol Date: 1992-02 Impact factor: 10.422
Authors: Yun J Kim; Masanori Ichise; James R Ballinger; Douglas Vines; Sean S Erami; Tatsuro Tatschida; Anthony E Lang Journal: Mov Disord Date: 2002-03 Impact factor: 10.338
Authors: Morten Ziebell; Gerda Thomsen; Gitte M Knudsen; Robin de Nijs; Claus Svarer; Aase Wagner; Lars H Pinborg Journal: Eur J Nucl Med Mol Imaging Date: 2006-07-29 Impact factor: 9.236
Authors: Michael Nocker; Klaus Seppi; Eveline Donnemiller; Irene Virgolini; Gregor K Wenning; Werner Poewe; Christoph Scherfler Journal: Eur J Nucl Med Mol Imaging Date: 2012-03-30 Impact factor: 9.236
Authors: S Hesse; C Oehlwein; H Barthel; J Schwarz; D Polster; A Wagner; O Sabri Journal: J Neural Transm (Vienna) Date: 2006-02-06 Impact factor: 3.575